Rory B. Riggs - Sep 28, 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
Director
Signature
/s/ Jason Mehar, as Attorney-in-Fact for Rory B. Riggs
Stock symbol
RPRX
Transactions as of
Sep 28, 2021
Transactions value $
-$4,688,288
Form type
4
Date filed
9/30/2021, 03:56 PM
Previous filing
Jul 2, 2021
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$1.47M -40K -5.88% $36.75 640K Sep 28, 2021 Direct F1
transaction RPRX Class A Ordinary Shares Sale -$900K -24.6K -3.85% $36.50 615K Sep 29, 2021 Direct F2
transaction RPRX Class A Ordinary Shares Other +2.33K +0.38% 617K Sep 29, 2021 Direct F3, F4
transaction RPRX Class A Ordinary Shares Other +5.3K +0.86% 623K Sep 29, 2021 Direct F4, F5
transaction RPRX Class A Ordinary Shares Other +8.64K +1.39% 631K Sep 29, 2021 Direct F4, F6
transaction RPRX Class A Ordinary Shares Sale -$1.26M -34.6K -3.71% $36.31 899K Sep 29, 2021 By New Ventures Select F7
transaction RPRX Class A Ordinary Shares Other -110K -12.21% 789K Sep 29, 2021 By New Ventures Select F8
transaction RPRX Class A Ordinary Shares Sale -$805K -22.2K -0.64% $36.31 3.43M Sep 29, 2021 By New Ventures I LLC F7
transaction RPRX Class A Ordinary Shares Other -512K -14.92% 2.92M Sep 29, 2021 By New Ventures I LLC F9
transaction RPRX Class A Ordinary Shares Sale -$257K -7K -0.34% $36.67 2.07M Sep 29, 2021 By New Ventures III LLC F10
transaction RPRX Class A Ordinary Shares Other -315K -15.18% 1.76M Sep 29, 2021 By New Ventures III LLC F11
holding RPRX Class A Ordinary Shares 15K Sep 28, 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPRX LP interests in RPI US Partners 2019, LP Gift $0 -7.69K -1.42% $0.00 534K Sep 10, 2021 Class A Ordinary Shares 76.9K Direct F12, F13, F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $36.96 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.15 to $36.87 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F3 Pro rata distribution from New Ventures Select, of which the Reporting Person has voting and investment control.
F4 Pro rata distribution from a limited liability company of which the Reporting Person is a member.
F5 Pro rata distribution from New Ventures I LLC, of which the Reporting Person has voting and investment control.
F6 Pro rata distribution from New Ventures III LLC, of which the Reporting Person has voting and investment control.
F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $36.50 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 New Ventures Select distributed these shares to its members on a pro rata basis, for no consideration.
F9 New Ventures I LLC distributed these shares to its members on a pro rata basis, for no consideration.
F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.62 to $36.75 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11 New Ventures III LLC distributed these shares to its members on a pro rata basis, for no consideration.
F12 No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
F13 The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.
F14 Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.